GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cabio Biotech (Wuhan) Co Ltd (SHSE:688089) » Definitions » 3-Year Sharpe Ratio

Cabio Biotech (Wuhan) Co (SHSE:688089) 3-Year Sharpe Ratio : 0.20 (As of Jul. 16, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Cabio Biotech (Wuhan) Co 3-Year Sharpe Ratio?

The 3-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past three years. As of today (2025-07-16), Cabio Biotech (Wuhan) Co's 3-Year Sharpe Ratio is 0.20.


Competitive Comparison of Cabio Biotech (Wuhan) Co's 3-Year Sharpe Ratio

For the Biotechnology subindustry, Cabio Biotech (Wuhan) Co's 3-Year Sharpe Ratio, along with its competitors' market caps and 3-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cabio Biotech (Wuhan) Co's 3-Year Sharpe Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cabio Biotech (Wuhan) Co's 3-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Cabio Biotech (Wuhan) Co's 3-Year Sharpe Ratio falls into.


;
;

Cabio Biotech (Wuhan) Co 3-Year Sharpe Ratio Calculation

The 3-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last three years. A stock / portfolio's 3-Year Sharpe Ratio can be calculated by dividing the difference between the three-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past three years.


Cabio Biotech (Wuhan) Co  (SHSE:688089) 3-Year Sharpe Ratio Explanation

The 3-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past three years. It is calculated as the annualized result of the average three-year monthly excess returns divided by its standard deviation in the three-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Cabio Biotech (Wuhan) Co 3-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Cabio Biotech (Wuhan) Co's 3-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cabio Biotech (Wuhan) Co Business Description

Traded in Other Exchanges
N/A
Address
No. 999, Gaoxin Avenue, East Lake New Technology Development Zone, Hubei Province, Wuhan, CHN, 430075
Cabio Biotech (Wuhan) Co Ltd is a biotechnology company, engaged in Research & Development, production and sales of polyunsaturated fatty acids ARA, algae oil DHA and SA, natural B-carotene and other series products. The products are used in infant formula, dietary nutrition supplements and health Food, special medical formula food and other fields. The company's product sales area covers China, the United States, Europe, Australia, New Zealand, South Korea, and Southeast Asia.
Executives
Shang Yun Core technical personnel
Xiao Min senior management
Wang Hua Biao Directors, senior managers
Geng An Feng senior management
Du Bin Director
Yi Hua Rong senior management
Ma Tao senior management
Li Xiang Yu senior management
Wu Yu Jun Supervisors
Wang Zhi Ming senior management
Lu Shu Huan Core technical personnel
Yi De Wei Director

Cabio Biotech (Wuhan) Co Headlines

No Headlines